Browse > Article

Human Activated Lymphocyte Treated with Anti-CD3, CD16, CD56 Monoclonal Antibody and IL-2  

Hong, Seon-Min (Biocell Co. Immune Research Institute)
Lee, Dong-Wook (Biocell Co. Immune Research Institute)
Kang, Jin-Gu (Department of Medicine, Yonsei University College of Medicine)
Kim, Han-Soo (Department of Medicine, Yonsei University College of Medicine)
Cho, Sung-Hoon (Biocell Co. Immune Research Institute)
Publication Information
IMMUNE NETWORK / v.5, no.1, 2005 , pp. 11-15 More about this Journal
Abstract
Background: Throughtout the last three decades, the therapy of leukemias and lymphoma has set the stage for curative cancer therapy in systemic malignant disease. This was the result of an integrated work of basic reaserch and clinical investigators leading to more aggressive albeit tolerable protocol of chemotherapy and radiotherapy. High dose therapy marks the most elaborated strategies in this field today. However, intensification of conventional therapeutic modalities as mentioned has to be based on new approaches and the exploration of new antineoplastic mechanisms. This insight has resulted in immune therapy of cancer. Among the cells of the immune system, natural killer (NK) cells and T cells are of major interest for the development of therapeutic strategies. Methods: Cytotoxicity to target cells was measured by LDH release method, Characterization of activated lymphocyte was measured by Flow cytometry analysis. Anti-CD3, 16, 56 monoclonal antibody and IL-2 were used for the activation of NK and T cell. The analysis of effect of activated lymphocyte, in vivo, were used by Balb/c nude mouse. Results and Conclusion: Cytotoxicity to K562 cells was significantly higher in the mixture group of NK and T cells than that of a group of activating T cells. The survivors and the rate of reduction of size of tumor craft of nude mouse group treatment with activated lymphocyte was higher than that of the group without treatment with activated lymphocyte. Therefore, this results are suggested that the activated lymphocytes by anti-CD3, CD16 and CD56 can reduce the malignancy effect of lymphoma.
Keywords
Activated lymphocyte; CD3; CD16; CD56; IL-2; natural killer cell; T cell; human; nude mouse; lymphoma; K562; raji;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Podack ER: Execution and suicide: cytotoxic lymphocytes enforce Draconian laws through separate molecular pathways. Curr Opin Immunol 7;11-16, 1995   DOI   PUBMED   ScienceOn
2 Liu CC, Walsh Cm, Young JD: Perforin: structure and function. Immunol Today 16;194-201, 1995   DOI   ScienceOn
3 Henkart PA, Williams MS, Zacharchuk CM, Sarin A: Do CTL kill target cells by inducing apoptosis? Semin Immunol 9;135-144, 1997
4 Rosenberg SA: Lymphokine-activated killer cells. A new approach to the immunotherapy of cancer. J Natl Cancer Inst 75;595-601, 1985   PUBMED
5 Azzoni L, Kamoun M, Salcedo TW, Kanakaraj P, Perussia B: Stimulation of Fc gamma RTIIIA results in phospholipase C-gamma 1 tyrosine phosphorylation and p56lck activation. J Exp Med 176;1745-1750, 1992   DOI   ScienceOn
6 Berke G: The CTL kiss of death. Cell 81;9-12, 1995   DOI   PUBMED   ScienceOn
7 Oda H, Oda H, Hayashi M, Cho SH: Adoptive lymphocyte immunotherapy in Non-Hodgkin's lymphoma (NHL). Biotherapy 18;333-338, 2004
8 Morgan DA, Rusetti FW, Gallo R: Selective in vitro growth of T lymphocytes from normal human bone marrow. Sciences 193;1007-1009, 1976   DOI
9 Rosenberg SA: Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 18;175-182, 1997   DOI   PUBMED   ScienceOn
10 Klein C, Philippe N, Le Deist F, Fraitag S, Prost C, Durandy A, Fischer A, Griscelli C: Partial albinism with immunodeficiency (Griscelli syndrome). J Pediatr 125;886-895, 1994   DOI   PUBMED
11 Boon T, Couline PG, van den Eynde B: Tumor antigen recognized by T cells. Immunol Today 18;267-268, 1997   PUBMED
12 Stinchcombe JC, Grffiths GM: Regulated secretion from hemopoietic cells. J Cell BioI 147;1-6, 1999
13 Rosenberg S, Lotze M, Muul L: A progress report on the treatment of 157 patients with advanced cancer using lvrnphokine-activated killer cells and interleukon-2 or high dose interleukin-2 alone. N Engl J Med 316;889-897, 1987   DOI   PUBMED   ScienceOn
14 Taga K, Yamaguchi A, Bloom ET, Tosato G: Target-induced death by apoptosis in human lymphokine-activated natural killer cells. Blood 87;2411-2418, 1996   PUBMED
15 Berke G: The Fas-based mechanism of lymphocytotoxicity. Hum Immunol 54;1-7, 1997   DOI   PUBMED   ScienceOn
16 Herberman RB: Cancer Immunotherapy with Natural Killer Cells. Seminars in Oncology 3;27-30, 2002